Direct answer:The entry of pharmaceutical preparations into the United States should be based on the identification of product categories and legal listings, and the coordination of the physical production facility registration, U.S. agent, Labeler Code, product packaging NDC, Drug Listing and labelling clearance. The steps are interrelated, but registration, coding and listing are not a substitute for the required listing approval; The DMF is technical information support and is not an independent listing permit.

The registration of a listing is made after confirmation of the legal listing conditions applicable to the product. OTC status does not necessarily imply the application of monographs; The submission of a DMF or the acquisition of a NDC does not automatically allow a product that does not meet the listing requirements to be sold legally.

First check the product categories and the legal basis for listing

(c) To organize the intended use, composition, formulation, route of delivery, declaration and manner of sale and to determine whether it is a human drug. product-specific identification of whether approved NDA, ANDA are required, or may meet statutory requirements such as the application of OTC Monochorph; Biological products and other special types need to be judged separately.

The DMF may, where appropriate, support the applicant’s reference to technical information, but does not grant separate listing qualifications. For relevant information, seeDMF Guide to Technical Documentation; I'll see you at the border.OTC Monograph Service。

II. Listing actual enterprises, facilities and liability relationships

Identify manufacturing, packaging, labelling, brand distribution, importation and U.S. agent parties, check which sites are to be registered, who is responsible for listing and who is the corresponding subject of the code according to the actual activity. Brand companies, factories, Labeler and U.S. agents cannot be considered the same role.

The offshore facility must be registered before the drug is to be imported and provide information on the application of U.S. agent and known importers. Detailed information on facilitiesGuidance on the registration and maintenance of facilities。

III. Verification of the registration of the facility and pre-information on Labeler Code

The physical location is checked separately from company information, DUNS, FDA contacts, authorizations and accepted records. The facility information was submitted differently from the Labeler Code request and should not skip another applicable matter by first obtaining one of its numbers.

Confirms availability when Labeler Code is available; After the first request for a distribution, an update with the code must be confirmed in accordance with the FDA description before the listing is linked.

IV. Prior alignment of labelling clearance and product packaging data

The labels should be reviewed around the established listing path and the true formulation. The OTC project verification applies to the Drug Facts content and format and corresponding product conditions; Prescription drug projects are checked against requirements such as the corresponding labels and approved information and cannot be applied to a generic OTC file.

Data on labels, agent type, intensity, route of delivery, packaging and related facilities should be aligned prior to listing. The review delivery may include a list of issues, amendments and a version of the review, as detailed below.Pharmaceutical labelling services; The label clearance is not equal to the FDA approval.

V. Product-specific submission of NDC and Drug Listing information

Once subject, code, label and product data are confirmed, the corresponding listing of SPL is prepared, the information on product and packaging levels, active and non-active ingredients, label graphics and production facilities is checked, feedback from the reprocessing system is submitted and the receipt record is maintained.

Product packing codes, listings and NDC Directory queries are of individual use and cannot be considered listing permission. See the detailed process and current formatDrug Listing and NDC Guide。

VI. Integrating production, imports and maintenance into the same plan

In addition to the registration of listings, the application of cGMPs, product quality and import requirements still need to be met. The facility’s annual renewal window is from 1 October to 31 December, and will be updated as required for the change of the project list and will be updated or certified without change on an annual basis.

Establishment of facility and product correspondence forms, responsible persons and information version records. Changes in formulation, labelling, packaging, production site or marketing status should be accompanied by a check of the relevant records, and not all maintenance can be determined to be complete at the extended facility alone.

VII. What are the pre-advisory preparations, and how are the cycles and costs judged?

  • Product uses, formulations, agent type intensity, mode of delivery and current labels.
  • Listed on the basis, approved or topical assessment and pending issues.
  • Relationships between manufacturing, packaging labelling, brand distribution and importation.
  • DUNS, facility registration, Labeler Code, NDC and listing records are available.
  • The person responsible for the proposed shipment time, submission of the authorization, internal information and maintenance.

The overall cycle depends on listing basis and technical information gaps, physical verification, labelling modifications and various types of submissions. The quotation should split the path judgement, registration, code, listing, label and maintenance, indicate whether U.S. agent, third-party technical work and applicable official user fees are separate and do not commit to a fixed “end-of-process” cycle applicable to all medicines.

Official sources and service portals

View pharmaceutical preparations FDA compliance services and preparations

Submission of business and product summaries, terms of reference and quotations

Official data checks and updates: 2026-11-06. Author: Mr. Otsun; Audit: Mr. Toto. Specific requirements are based on products, business activities and current FDA applicable rules.

Focus of this paper on relevant topics

This paper summarizes the records of pharmaceutical facilities, business roles and products by project order; Annual maintenance matters can be found in the register and information maintenance of pharmaceutical businesses, and the differences between Labeler Code, NDC and specific listings can be found in the base guide.

Continue reading and preparation

Further consolidation of project information is availableRegistration and annual maintenance of pharmaceutical facilities; The scope, processing cycles and costs are shown on the corresponding service page.